<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03644966</url>
  </required_header>
  <id_info>
    <org_study_id>2017564</org_study_id>
    <nct_id>NCT03644966</nct_id>
  </id_info>
  <brief_title>Probiotics and Multi-Drug Resistant Urinary Tract Infection</brief_title>
  <official_title>Probiotic and Effects on Multi-Drug Resistant Urinary Tract Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ochsner Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is a single-site randomized, double blinded placebo-controlled in females
      with recurrent multi-drug resistant (MDR) urinary tract infections(UTI). Our study
      hypothesizes that a novel probiotic strain improves antibiotic sensitivity patterns in these
      former MDR UTIs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aims of this study are (1) to evaluate the effects of six months of probiotic therapy in
      addition to standard of care in changing sensitivity patterns of MDR bacteria causing
      recurrent UTI, (2) analyze the genetic composition of MDR bacterial isolates causing
      recurrent UTI before and after administration of probiotic vs. placebo, with standard of care
      antibiotics.

      Study subjects will be asked to take a either a probiotic supplement or placebo at a dose of
      1 caplet per day for 24 weeks in addition to antibiotic regimen. Subjects will be followed
      for 12 months. The outcome measure is the percent of probiotic ingestors vs placebo ingestors
      who experience a change in antibiotic susceptibility over this time period. The secondary
      outcome measure is the evaluation of genetic composition of bacteria recurring after
      probiotic vs. placebo administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2018</start_date>
  <completion_date type="Anticipated">November 29, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 29, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Resistance Pattern</measure>
    <time_frame>6-8 weeks after initial dose</time_frame>
    <description>The change in the quantity of antibiotics reported to be resistant per organism per culture per patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacterial isolate genomic characteristics</measure>
    <time_frame>12 months after initial dose</time_frame>
    <description>genomic sequencing of bacterial isolates to determine genetic identity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>UTI reduction</measure>
    <time_frame>12 months after initial dose</time_frame>
    <description>The quantity of reduction of all urinary tract infections (UTI) in treatment arm vs. placebo from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotics Quantity</measure>
    <time_frame>12 months after initial dose</time_frame>
    <description>The quantity of antibiotics prescribed in treatment arm vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare visit</measure>
    <time_frame>12 months after initial dose</time_frame>
    <description>The quantity of ER visits/urgent care visits/hospitalizations/outpatient clinic visits in treatment arm vs. placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of time for change in resistance</measure>
    <time_frame>12 months after initial dose</time_frame>
    <description>The amount of time it takes to note changes in antibiotic sensitivity patterns while on the treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity pattern post-probiotic therapy</measure>
    <time_frame>12 months after initial dose</time_frame>
    <description>The change in the quantity of antibiotics reported to be resistant per organism</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Urinary Tract Infections</condition>
  <condition>Recurrent UTI</condition>
  <condition>Antibiotic Resistant Infection</condition>
  <arm_group>
    <arm_group_label>Probiotic + Antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 subjects to receive probiotic supplement once daily for 6 months in capsule form, in addition to standard antibiotic regimen for treatment of UTI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Antibiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 subjects to receive placebo once daily for 6 months in capsule form, in addition to antibiotic regimen for treatment of UTI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacterium infantis</intervention_name>
    <description>Probiotics</description>
    <arm_group_label>Probiotic + Antibiotic</arm_group_label>
    <other_name>Align</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill manufactured to mimic probiotic tablet</description>
    <arm_group_label>Placebo + Antibiotic</arm_group_label>
    <other_name>Placebo (for Probiotic)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics</intervention_name>
    <description>Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women</description>
    <arm_group_label>Placebo + Antibiotic</arm_group_label>
    <arm_group_label>Probiotic + Antibiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, age 18-90

          -  Ability to void spontaneously

          -  Suffers from recurrent multi-drug resistant or extensively drug resistant urinary
             tract infections caused by E.coli, Klebsiella, Enterococcus, Citrobacter, Proteus,
             Enterobacter, Serratia and Providencia.

        Exclusion Criteria:

          -  Has staghorn renal calculi, chronic hydronephrosis, intermittent catherization,
             indwelling urinary catheters, urinary diversions, end stage renal disease on
             hemodialysis, transplantation, HIV, cirrhosis, pancreatitis, allergy to soy or
             milk/milk proteins or lactose intolerance

          -  Pregnant or breastfeeding

          -  Currently taking probiotics. 4 week washout.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melissa Montgomery, MD</last_name>
    <phone>504-842-4083</phone>
    <email>memontgomery@ochsner.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mhy-Lanie Adduru, MD</last_name>
    <phone>504-842-9971</phone>
    <email>mhylanie.adduru@ochsner.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ochsner Health System</name>
      <address>
        <city>Jefferson</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mhy-Lanie Adduru, MD</last_name>
      <phone>504-842-9971</phone>
      <email>mhylanie.adduru@ochsner.org</email>
    </contact>
    <contact_backup>
      <last_name>Maria Latsis</last_name>
      <phone>504-842-3115</phone>
      <email>mlatsis@ochsner.org</email>
    </contact_backup>
    <investigator>
      <last_name>Melissa M Montgomery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanna Togami, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Naderi A, Kasra-Kermanshahi R, Gharavi S, Imani Fooladi AA, Abdollahpour Alitappeh M, Saffarian P. Study of antagonistic effects of Lactobacillus strains as probiotics on multi drug resistant (MDR) bacteria isolated from urinary tract infections (UTIs). Iran J Basic Med Sci. 2014 Mar;17(3):201-8.</citation>
    <PMID>24847423</PMID>
  </reference>
  <reference>
    <citation>Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev. 2015 Dec 23;(12):CD008772. doi: 10.1002/14651858.CD008772.pub2. Review.</citation>
    <PMID>26695595</PMID>
  </reference>
  <reference>
    <citation>Simmering JE, Tang F, Cavanaugh JE, Polgreen LA, Polgreen PM. The Increase in Hospitalizations for Urinary Tract Infections and the Associated Costs in the United States, 1998-2011. Open Forum Infect Dis. 2017 Feb 24;4(1):ofw281. doi: 10.1093/ofid/ofw281. eCollection 2017 Winter.</citation>
    <PMID>28480273</PMID>
  </reference>
  <reference>
    <citation>Barclay J, Veeratterapillay R, Harding C. Non-antibiotic options for recurrent urinary tract infections in women. BMJ. 2017 Nov 23;359:j5193. doi: 10.1136/bmj.j5193.</citation>
    <PMID>29170359</PMID>
  </reference>
  <reference>
    <citation>Vahedi-Shahandashti R, Kasra-Kermanshahi R, Shokouhfard M, Ghadam P, Feizabadi MM, Teimourian S. Antagonistic activities of some probiotic lactobacilli culture supernatant on Serratia marcescens swarming motility and antibiotic resistance. Iran J Microbiol. 2017 Dec;9(6):348-355.</citation>
    <PMID>29487733</PMID>
  </reference>
  <reference>
    <citation>Lau CS, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016 Feb 22;9:27-37. doi: 10.2147/IJGM.S98280. eCollection 2016.</citation>
    <PMID>26955289</PMID>
  </reference>
  <reference>
    <citation>Favier C, Neut C, Mizon C, Cortot A, Colombel JF, Mizon J. Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease. Dig Dis Sci. 1997 Apr;42(4):817-22.</citation>
    <PMID>9125655</PMID>
  </reference>
  <reference>
    <citation>Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011 Mar 1;52(5):e103-20. doi: 10.1093/cid/ciq257. Review.</citation>
    <PMID>21292654</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 6, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2018</study_first_posted>
  <last_update_submitted>August 22, 2018</last_update_submitted>
  <last_update_submitted_qc>August 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ochsner Health System</investigator_affiliation>
    <investigator_full_name>Melissa Montgomery, MD</investigator_full_name>
    <investigator_title>Urologist</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>multi-drug resistant UTI</keyword>
  <keyword>recurrent UTI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

